Corium had previously run its contract development and manufacturing organization (CDMO) from within the larger company, but decided to sell its stake in the business to Webster Equity Partners.
The standalone CDMO business will be known as Corium Pharma Solutions, which Webster will acquire through an investment of more than $400m (€408m). Of this total, $100m is comprised of an equity investment by Webster.
A spokesperson for the company confirmed that the CDMO will be jointly owned by Webster and Gurnet Point, with Corium having no stake in the business.
Previously, Gurnet Point acquired ownership of the Corium business in 2018 for a cost of $500m.
According to the companies, the CDMO will focus on expanding its drug and consumer product capabilities, whilst also maintaining its current manufacture and supply of Corium’s product, Adlarity (donepezil transdermal system).
Corium Pharma Services will be able to offer its transdermal…
